论文部分内容阅读
目的:针对宫颈癌治疗中新辅助化疗的临床应用疗效进行研究。方法:选择自2012年1月~2014年6月我院收治且临床资料完整的宫颈癌患者76例,采用新辅助治疗,1个月后74例行广泛子宫切除术及盆腔淋巴结清除术,2例患者化疗后临床体征不佳行放疗,记录患者病理改变。结果:临床分期为Ⅰb2、Ⅱa的患者治疗效果大于Ⅱb,有效率可达100.0%,分化程度G1、G3的患者治疗效果大于G2,病理分型为鳞癌的患者治疗效果相对其他类型要差,有效率仅89.6%。结论:对于分期为Ⅰb2、Ⅱa,病理分型除鳞癌以外,分化程度为G1、G3的宫颈癌患者,采用新辅助化疗能取得理想的临床疗效,值得临床推广使用。
Objective: To study the clinical effect of neoadjuvant chemotherapy in the treatment of cervical cancer. Methods: 76 patients with cervical cancer who were admitted to our hospital from January 2012 to June 2014 with complete clinical data were treated with neoadjuvant therapy. One month later, 74 patients underwent extensive hysterectomy and pelvic lymphadenectomy. 2 After chemotherapy, patients with poor clinical signs of radiotherapy, recording pathological changes in patients. Results: The therapeutic effect of patients with stage Ⅰb2 and Ⅱa was higher than that of Ⅱb and the effective rate was 100.0%. The treatment effect of patients with G1 and G3 differentiation was greater than that of G2. The treatment effect of patients with squamous cell carcinoma was worse than that of other types, Efficiency is only 89.6%. Conclusions: Neoadjuvant chemotherapy can achieve the desired clinical effect for patients with cervical cancer with G1, G3 differentiation stages except Ⅰb2, Ⅱa and pathological type of squamous cell carcinoma, which is worthy of clinical promotion.